Article Sidebar

PDF
Date Published: 25/04/2022
Abstract Views: 361
Views PDF: 149
DOI: https://doi.org/10.51298/vmj.v512i1.2210
Issue
Vol. 512 No. 1 (2022)
Section
Các bài báo
How to Cite
Công Long, N. ., & Nghệ Tĩnh, N. . (2022). RADIOFREQUENCY ABLATION COMBINED WITH TRANSARTERIAL CHEMOEMBOLIZATION FOR INTERMEDIATE HEPATOCELLULAR CARCINOMA. Vietnam Medical Journal, 512(1). https://doi.org/10.51298/vmj.v512i1.2210

RADIOFREQUENCY ABLATION COMBINED WITH TRANSARTERIAL CHEMOEMBOLIZATION FOR INTERMEDIATE HEPATOCELLULAR CARCINOMA

Nguyễn Công Long1,, Nguyễn Nghệ Tĩnh1
1 Department of Gastroenterology and Hepatology, Bach Mai Hospital

Main Article Content

Abstract

Objectives: Radiofrequency ablation therapy (RFA) combined with transarterial chemoembolization (TACE) (combination therapy) is effective for intermediate hepatocellular carcinoma (HCC). The aim of this study was the long-term effects of combination therapy for intermediate HCC. Methods: A total of 42 patients with hepatocellular carcinoma treated with transarterial chemoembolization combined RFA. Results: The mean age was 63.6 year. The single tumor accounted for 17(40.5%). The cause hepatocellular carcinoma was hepatitis B, 36 patients (85.7%). For overall survival rate of the 42 patients who underwent transarterial chemoembolization combined with RFA were 8.261 years. Conclusion: The combination of TACE and RFA is a safe and effective therapy in patients with intermediate HCC.

Article Details

Keywords

hepatocellular carcinoma, radiofrequency ablation, transarterial chemoembolization

References

1. Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209-249.
2. Bosch, F., et al., Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5 Suppl 1):S5-S16. Gastroenterology, 2004. 127: p. S5-S16.
3. Lencioni, R., et al., Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist, 2010. 15 Suppl 4: p. 42-52.
4. Tanaka, M., et al., Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma. Hepatol Res, 2014. 44(2): p. 194-200.
5. Lo, C.M., et al., Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 2002. 35(5): p. 1164-71.